Imatinib Mesylate (CGP-57148B, STI-571) | 1625

An inhibitor of the bcr-abl tyrosine kinase. It acts by binding to the ATP binding site of bcr-abl. Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. It inhibits EOL-1 cell viability (IC₅₀ = 0.5 nM), phosphorylation of a fusion protein (IC₅₀ = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC₅₀ = 0.17 nM).

Imatinib (STI-571) is an inhibitor of the bcr-abl tyrosine kinase. It acts by binding to the ATP binding site of bcr-abl.

1625 | Imatinib Mesylate (CGP-57148B, STI-571) DataSheet

Alternate Name/Synonyms: CGP-57148B, STI-571

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 220127-57-1

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₉H₃₁N₇O.CH₄SO₃

Molecular Weight: 589.71

Cell-Permeable?: Yes

Purity: ≥99% by HPLC

Solubilities: DMSO (100 mg/ml)

Handling: Protect from air and moisture

Country of Origin: USA

Tag Line: A bcr-abl tyrosine kinase inhibitor

MDL Number: MFCD04307699

PubChem CID: 123596

SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5.CS(=O)(=O)O

InChi: InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33- 29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17- 36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,12H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4)

InChi Key: YLMAHDNUQAMNNX-UHFFFAOYSA-N